ecteinascidin 743 has been researched along with Genital Neoplasms, Female in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aissaoui, D; Essafi-Benkhadir, K; Souid, S; Srairi-Abid, N | 1 |
| Kim, HJ; Kim, JW; Kim, M; Lee, KH; Suh, DH | 1 |
2 review(s) available for ecteinascidin 743 and Genital Neoplasms, Female
| Article | Year |
|---|---|
Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response.
Topics: Antineoplastic Agents, Alkylating; Biomarkers, Pharmacological; BRCA1 Protein; BRCA2 Protein; Breast Neoplasms; Female; Genital Neoplasms, Female; Genomics; Humans; Trabectedin | 2020 |
Major clinical research advances in gynecologic cancer in 2015.
Topics: Biomedical Research; Breast Neoplasms; Combined Modality Therapy; Dioxoles; Endometrial Neoplasms; Female; Genital Neoplasms, Female; Humans; Immunotherapy; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Papillomavirus Vaccines; Precision Medicine; Tetrahydroisoquinolines; Trabectedin; Uterine Cervical Neoplasms; Uterine Neoplasms | 2016 |